American Oriental Bioengineering, Inc. (AOBI)
USD 0.0
(-50.0%)
USD 0.0
(-50.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2012 | 60.54 Million USD | -5.12% |
| 2011 | 63.81 Million USD | 122.6% |
| 2010 | 28.66 Million USD | -25.45% |
| 2009 | 38.45 Million USD | -31.21% |
| 2008 | 55.89 Million USD | 135.8% |
| 2007 | -156.12 Million USD | -103.34% |
| 2006 | -76.78 Million USD | -42.68% |
| 2005 | -53.81 Million USD | -754.69% |
| 2004 | -6.29 Million USD | -61.91% |
| 2003 | -3.88 Million USD | -183.66% |
| 2002 | -1.37 Million USD | -1803768.42% |
| 2001 | -76.00 USD | -100.03% |
| 2000 | 235.35 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2013 Q1 | 56.26 Million USD | -7.08% |
| 2013 Q3 | 89.53 Million USD | 55.23% |
| 2013 Q2 | 57.68 Million USD | 2.52% |
| 2012 Q1 | 62.26 Million USD | -2.43% |
| 2012 FY | 60.54 Million USD | -5.12% |
| 2012 Q4 | 60.54 Million USD | 48.46% |
| 2012 Q3 | 40.78 Million USD | -46.26% |
| 2012 Q2 | 75.88 Million USD | 21.89% |
| 2011 FY | 63.81 Million USD | 122.6% |
| 2011 Q4 | 63.81 Million USD | 57.18% |
| 2011 Q3 | 40.59 Million USD | -19.05% |
| 2011 Q2 | 50.15 Million USD | 312.12% |
| 2011 Q1 | 12.16 Million USD | -57.55% |
| 2010 Q2 | 29.4 Million USD | -12.72% |
| 2010 Q1 | 33.68 Million USD | -12.4% |
| 2010 Q3 | 30.62 Million USD | 4.18% |
| 2010 FY | 28.66 Million USD | -25.45% |
| 2010 Q4 | 28.66 Million USD | -6.41% |
| 2009 FY | 38.45 Million USD | -31.21% |
| 2009 Q1 | 52.66 Million USD | -5.78% |
| 2009 Q2 | 24.83 Million USD | -52.84% |
| 2009 Q3 | 13.63 Million USD | -45.11% |
| 2009 Q4 | 38.45 Million USD | 182.06% |
| 2008 Q1 | -148.45 Million USD | 4.91% |
| 2008 FY | 55.89 Million USD | 135.8% |
| 2008 Q4 | 55.89 Million USD | 159.51% |
| 2008 Q3 | -93.93 Million USD | 29.74% |
| 2008 Q2 | -133.69 Million USD | 9.94% |
| 2007 Q1 | -82.99 Million USD | -8.1% |
| 2007 Q2 | -97.21 Million USD | -17.13% |
| 2007 Q3 | -160.58 Million USD | -65.18% |
| 2007 Q4 | -156.12 Million USD | 2.78% |
| 2007 FY | -156.12 Million USD | -103.34% |
| 2006 Q3 | -60.9 Million USD | -0.73% |
| 2006 FY | -76.78 Million USD | -42.68% |
| 2006 Q1 | -77.17 Million USD | -43.41% |
| 2006 Q2 | -60.46 Million USD | 21.65% |
| 2006 Q4 | -76.78 Million USD | -26.06% |
| 2005 Q4 | -53.81 Million USD | -251.05% |
| 2005 Q3 | -15.32 Million USD | -56.83% |
| 2005 Q2 | -9.77 Million USD | -38.2% |
| 2005 Q1 | -7.07 Million USD | -12.33% |
| 2005 FY | -53.81 Million USD | -754.69% |
| 2004 Q3 | -647.12 Thousand USD | 81.23% |
| 2004 Q4 | -6.29 Million USD | -872.98% |
| 2004 FY | -6.29 Million USD | -61.91% |
| 2004 Q1 | -3.71 Million USD | 4.58% |
| 2004 Q2 | -3.44 Million USD | 7.08% |
| 2003 Q2 | -2.71 Million USD | -59.76% |
| 2003 Q1 | -1.69 Million USD | -23.89% |
| 2003 FY | -3.88 Million USD | -183.66% |
| 2003 Q4 | -3.88 Million USD | -37.99% |
| 2003 Q3 | -2.81 Million USD | -3.87% |
| 2002 Q4 | -1.37 Million USD | -101.56% |
| 2002 Q1 | -76.00 USD | 0.0% |
| 2002 Q2 | -1.03 Million USD | -1361721.05% |
| 2002 Q3 | -680.16 Thousand USD | 34.28% |
| 2002 FY | -1.37 Million USD | -1803768.42% |
| 2001 Q2 | -76.00 USD | -100.02% |
| 2001 Q3 | 333.25 Thousand USD | 438596.05% |
| 2001 Q4 | -76.00 USD | -100.02% |
| 2001 FY | -76.00 USD | -100.03% |
| 2001 Q1 | 315.03 Thousand USD | 33.86% |
| 2000 Q2 | 439.38 Thousand USD | 147.82% |
| 2000 Q1 | 177.29 Thousand USD | 0.0% |
| 2000 Q4 | 235.35 Thousand USD | 10209.71% |
| 2000 FY | 235.35 Thousand USD | 0.0% |
| 2000 Q3 | -2328.00 USD | -100.53% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 4621913.053% |
| Arch Therapeutics, Inc. | 5.64 Million USD | -971.915% |
| Evofem Biosciences, Inc. | 42.79 Million USD | -41.485% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 24355.168% |
| Rebus Holdings, Inc. | 305 Thousand USD | -19751.066% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 1060.354% |
| Qrons Inc. | 351.42 Thousand USD | -17128.543% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -9628.35% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | -39.397% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 296776.553% |
| Skye Bioscience, Inc. | -5.72 Million USD | 1158.235% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | -284.1% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -1370.262% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -14966.792% |
| SQZ Biotechnologies Company | -36.23 Million USD | 267.078% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -2600.244% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -6430.054% |
| Mesoblast Limited | 55.85 Million USD | -8.392% |
| Marizyme, Inc. | 18.56 Million USD | -226.058% |
| Genus plc | 190.6 Million USD | 68.234% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -2607.974% |
| Pharming Group N.V. | 109.8 Million USD | 44.86% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -6938.231% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -4887.754% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -8803.787% |
| ContraFect Corporation | -6.02 Million USD | 1104.742% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -44868.955% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -5140.11% |
| IMV Inc. | 7.67 Million USD | -689.33% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | -1000.452% |
| MultiCell Technologies, Inc. | 90.04 USD | -67243070.813% |
| ONE Bio Corp. | 9.04 Million USD | -569.751% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 8348.987% |
| RVL Pharmaceuticals plc | 12.94 Million USD | -367.679% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | -4325.953% |
| Q BioMed Inc. | 4.06 Million USD | -1391.272% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | -98.16% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -5908.216% |
| Biomind Labs Inc. | 711.4 Thousand USD | -8410.765% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -2928.208% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | -372.77% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -16731.823% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -43207.596% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -304655.378% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -2649.604% |
| GB Sciences, Inc. | 1.74 Million USD | -3365.072% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 33043.256% |
| HST Global, Inc. | 96.79 Thousand USD | -62451.787% |
| CSL Limited | 10.52 Billion USD | 99.425% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -29260.213% |
| Halberd Corporation | 144.72 Thousand USD | -41736.189% |
| Enzolytics Inc. | 981.65 Thousand USD | -6067.716% |
| Agentix Corp. | 37.63 Thousand USD | -160793.282% |
| Resverlogix Corp. | 6.45 Million USD | -838.548% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 9095.207% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 102.984% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 228.788% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -756.258% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -2135.303% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 784.914% |
| AVAX Technologies, Inc. | -5.9 Million USD | 1125.642% |
| Zenith Capital Corp. | 10.06 Thousand USD | -601507.224% |
| Genscript Biotech Corporation | -1.06 Billion USD | 105.705% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -30107.627% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -2437.506% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -36703.914% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 330625.991% |
| Kadimastem Ltd | -253.1 Thousand USD | 24021.483% |
| Helix BioMedix, Inc. | -2.57 Million USD | 2455.836% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | -198.608% |
| BioStem Technologies, Inc. | 4.47 Million USD | -1253.882% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -29984.247% |
| LadRx Corporation | -2.03 Million USD | 3073.075% |
| Cell Source, Inc. | 9.23 Million USD | -555.827% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -9432.257% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -9432.257% |
| NovAccess Global Inc. | 2.17 Million USD | -2679.285% |
| Affymax, Inc. | -5.59 Million USD | 1181.754% |
| Itoco Inc. | 228.3 Thousand USD | -26419.678% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -44422.536% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | -1121.419% |
| Mobile Lads Corp. | 484.23 Thousand USD | -12403.459% |
| CytoDyn Inc. | 20.26 Million USD | -198.814% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 9358021.329% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 653353.452% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | -685.696% |
| SYBLEU INC | 473.71 Thousand USD | -12681.077% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | -1258.435% |
| International Stem Cell Corporation | 2.59 Million USD | -2237.674% |
| Bioxytran, Inc. | 1.89 Million USD | -3088.441% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -96908.237% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -2676.182% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -1663.126% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | -607.889% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -7736.552% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 4943.66% |
| Neutra Corp. | 52.18 Thousand USD | -115916.922% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 2532.533% |
| PureTech Health plc | -167.19 Million USD | 136.212% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 24821.835% |
| IXICO plc | -4.44 Million USD | 1462.236% |
| IntelGenx Technologies Corp. | 13.21 Million USD | -358.021% |
| Gelesis Holdings, Inc. | 54.85 Million USD | -10.382% |
| CSL Limited | 10.52 Billion USD | 99.425% |
| Cellectis S.A. | -43.81 Million USD | 238.173% |